Loading...
Patients with neurofibromatosis 2 (NF2) experience progressive growth of multiple intracranial and spinal tumors and have a very high risk for bilateral deafness and other neurological problems. Treatment traditionally consists of surgery or radiotherapy, both of which have high rates of complications and challenges posed by the presence of multiple target lesions. Now, researchers report on a study of 10 patients with NF2 who were treated with the angiogenesis inhibitor bevacizumab for a progressive vestibular schwannoma on a compassionate-use basis.
The researchers first conducted immunohistochemical analysis of tissue samples from 21 NF2-associated schwannomas, 22 sporadic schwannomas, and 9 normal spinal-nerve roots for expression of var…